Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Cyclo Therapeutics, Inc (CYTH)  
$1.47 0.02 (1.38%) as of 4:30 Thu 5/2


Download
   
Exchange: OTC Bulletin Board
Security Type: Common
Shares Out: 6,360,000
Market Cap: 9.35(M)
Last Volume: 43,465 Avg Vol: 33,977
52 Week Range: $0.93 - $2.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Related Products

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Cyclo Therapeutics is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. Co.'s primary drug candidate, Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), is used as a treatment for Niemann-Pick Type C disease (NPC). NPC is a cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. Co. is also exploring the use of cyclodextrins in the treatment of Alzheimer's disease. Co. sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 4,000,000 4,462,105
Total Buy Value $0 $0 $5,000,000 $5,344,218
Total People Bought 0 0 1 5
Total Buy Transactions 0 0 1 8
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 85
  Page 4 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Fine N Scott Chief Executive Officer   •       •      –    2020-04-24 4 B $0.10 $73,003 D/D 730,030 7,466,513 2.81 -11%     
   Ostronic Francis Patrick Director   •       •      –    2020-04-24 4 B $0.10 $100,000 D/D 1,000,000 2,355,890 2.39 -11%     
   Hrynkow Sharon Hemond Chief Scientific Officer   •       •      –    2020-04-24 4 A $0.10 $20,000 D/D 200,000 635,000     -
   Tate Jeffrey Chief Operating Officer   •       •      –    2020-04-24 4 A $0.10 $5,000 D/D 50,000 1,015,972     -
   Hrynkow Sharon Hemond Chief Scientific Officer   •       •      –    2019-09-27 4 A $0.00 $0 D/D 100,000 435,000     -
   Tate Jeffrey Chief Operating Officer   •       •      –    2019-09-27 4 A $0.00 $0 D/D 100,000 965,972     -
   Fine Joshua M Chief Financial Officer   •       •      –    2019-09-27 4 A $0.00 $0 D/D 50,000 648,000     -
   Fine N Scott Chief Executive Officer   •       •      –    2019-09-18 4 B $0.18 $1,750 D/D 10,000 6,736,483 2.73     -
   Shanahan William S Director   •       •      –    2019-09-17 4 B $0.19 $27,968 D/D 147,200 2,667,660 2.39     -
   Ostronic Francis Patrick Director   •       •      –    2019-09-16 4 B $0.19 $19,000 D/D 100,000 1,355,890 2.39     -

  85 Records found
  1  2  3  4    
  Page 4 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed